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Abstract: Combination pharmacotherapy has simplified and improved glaucoma medication 
regimens. This update focuses on the previous and recent studies on efficacy and tolerability 
profile of dorzolamide–timolol in adult ocular hypertension and open angle glaucoma patients. 
Dorzolamide–timolol has been shown to be efficacious and well tolerated in clinical trials and 
the adverse effects reflect those of the individual components.
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Introduction
Glaucoma is a worldwide epidemiological challenge affecting approximately 
4% of the global population.1–7 Research shows that by 2010, an estimated 
60.5 million people globally will be living with either angle closure glaucoma 
(ACG) or primary open angle glaucoma (POAG).8 Elevated intraocular pressure 
is the most important modifiable risk factor for glaucoma and hence lowering 
of IOP is the goal of glaucoma therapy.9,10 Pharmacotherapy remains the chief 
management modality for the patients of glaucoma and ocular hypertension.9 
Topical antiglaucoma medications act either by decreasing aqueous production 
(beta adrenergic antagonists, carbonic anhydrase inhibitors [CAI]) or increasing 
aqueous outflow (prostaglandin derivatives, cholinergic agonists) or both (alpha-2 
adrenergic agonists).9 Treatment is started with monotherapy but in cases where 
monotherapy fails to attain the target IOP, other drugs are added.9,10 Factors that 
influence the choice of an agent are efficacy, safety profile, ease of administration 
and cost.11,12 Fixed drug combinations can help to avoid complex dosing schedules 
of multi drug glaucoma therapy and thus improve compliance.12,13 Several fixed 
combinations of commonly used IOP-lowering medications have been developed 
and are available in various markets worldwide. Most fixed combinations con-
tain timolol, as it can be dosed either once or twice daily and can be combined 
with prostaglandin analogs, adrenergic agonists, and CAIs.13 Cosopt® (Merck & 
Co., Inc.,Whitehouse Station, NJ, USA), a commonly available combination 
drug that consists of dorzolamide hydrochloride 2% and timolol maleate 0.5% 
was first commercially introduced in 1998. Each milliliter of Cosopt consists of 
22.26 mg dorzolamide hydrochloride and 6.83 mg timolol maleate with 0.0075% 
benzalkanoium chloride as preservative.14 This update focuses on the previous and 
recent studies on efficacy and tolerability profile of dorzolamide–timolol in adult 
ocular hypertension and open angle glaucoma patients.
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Mode of action, pharmacodynamic 
and pharmacokinetic profile
The pharmacodynamic properties of timolol and dorzolamide 
have been extensively reviewed elsewhere.15–17 As there is no 
direct pharmacodynamic interaction between the two drugs, 
a brief overview of the pharmacodynamic and pharmacoki-
netic profile of each drug is presented here.
Timolol is a non-selective β-blocker (β1 and β2) which 
has little or no local anesthetic, membrane stabilizing or 
sympathomimetic properties.16 Timolol lowers IOP by 
inhibiting aqueous humor production18–20 and it has been 
suggested that timolol down-regulates adenylate cyclase 
by inhibiting β2-adrenoceptor sites at the ciliary process.21 
Dorzolamide is a highly selective inhibitor of CA-II, an 
isoenzyme present on the ciliary process in the eye.15 
Inhibition of CA-II slows local bicarbonate production, 
decreases sodium and fluid transport and, consequently, 
decreases aqueous humor production and lowers IOP.17 
Because their mechanisms of action differ, they have an 
additive effect when administered together.22
Approximately 80% of the volume of topically admin-
istered eye drops is absorbed systemically within 15 to 30 
seconds of instillation.23 Chronic administration of dorzol-
amide leads to its accumulation in erythrocytes. Hepatic 
metabolism of dorzolamide produces N-desthyl metabolite 
which also binds to red blood cells but inhibits carbonic 
anhydrase I more than carbonic anhydrase II.24 Approximately 
24% to 32% of systemically absorbed dorzolamide is bound 
to plasma proteins.25
Urine is the major route of excretion for both parent and 
metabolite drug.26 There is a rapid decline of dorzolamide from 
red blood cells, on discontinuation of the medication. This is 
followed by a gradual decline due to an elimination phase 
half-life of approximately 4 months.27 However, in patients 
with glaucoma treated with dorzolamide 2% 3 times daily, 
plasma concentrations after 12 months were similar to those 
after 6 months (≈20 µmol/L).28 Because of its renal elimination, 
dorzolamide eyedrops are not recommended in patients with 
severe renal impairment. Topical dorzolamide has not been 
studied in patients with hepatic dysfunction, but should be used 
with caution as the drug undergoes hepatic metabolism.
Not much has been published on the pharmacokinetic 
characteristics of fixed combination of dorzolamide and 
timolol, accordingly the characteristics of individual 
components are being discussed.
Topical dorzolamide is absorbed through nasopharyngeal 
mucosa into systemic circulation.15 Biollaz et al have shown 
that plasma concentration of dorzolamide remained below 
level of detection after instillation of single or multiple doses 
of dorzolamide 2 or 3% in healthy volunteers.29 Dorzolamide 
undergoes slow metabolism by cytochrome P450 (CYP) 
2B1/2, CYP2E1 and CYP3A2.30
CAIs have been reported to improve ocular blood flow 
profile by causing ocular vasodilation through metabolic 
acidosis via elevated carbon dioxide levels.31 Topically 
administered dorzolamide–timolol has been shown to improve 
some markers of ocular blood flow in small studies (n = 15–30) 
in patients with POAG.32–35 Retinal arteriovenous time passage 
time from superior temporal artery to the corresponding vein 
was significantly shorter following 1 month of double masked 
treatment with dorzolamide–timolol twice daily (1.76 s) 
than with timolol 0.5% twice daily (2.13 s) (P = 0.01).35 
The fixed combination did not alter choroidal perfusion or 
retrobulbar hemodynamics relative to timolol 0.5% baseline 
in this randomized crossover comparison (n = 15).35 However, 
this finding contrasts with that of a crossover comparison 
of latanoprost 0.005% in which 1 month of non-blind 
treatment with dorzolamide–timolol significantly (P = 0.003) 
increased pulsatile ocular blood flow by 2.05 ÂµL/s relative 
to the timolol 0.5% baseline.32 Dorzolamide–timolol also 
significantly improved retrobulbar hemodynamic parameters 
relative to baseline in another randomized cross over 
comparative study with latanoprost.34 The fixed combination 
increased end diastolic velocity and decreased the resistance 
index in both the ophthalmic artery and short posterior ciliary 
artery. Improvements in ocular blood flow markers following 
treatment with dorzolamide 2%/timolol 0.5% generally 
exceeded those observed with latanoprost 0.005% once daily 
in 2 cross over randomized studies.32,34
A recent study has shown dorzolamide 2%/timolol 0.5% 
fixed combination increased blood flow significantly at the 
neuroretinal rim showing a combination of hypotensive and 
hemodynamic effects.36 Twenty-eight patients with early-
moderate glaucomatous damage treated with beta-blockers 
(6 months) with IOP values ranging from 18 to 22 mmHg 
at trough participated in this trial. After a 4-week washout 
period, patients were randomized in two groups: group I 
started with dorzolamide 2% monotherapy and group II with 
timolol 0.5% monotherapy for 4 weeks. After this period, 
both groups switched to dorzolamide 2%/timolol 0.5% fixed 
combination for 4 weeks. IOP, ocular diastolic perfusion 
pressure (ODPP), heart rate, and Scanning Laser Doppler 
Flowmetry measurements at the peripapillary retina and 
neuroretinal rim were taken at T0 (enrolment), T1 (wash out), 
T2 (monotherapy), and T3 (dorzolamide–timolol). Between 
T1 and T3, IOP decreased significantly in group I (-21.40%) Drug, Healthcare and Patient Safety 2010:2 75
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(P  0.001) and in group II (-21.25%) (P  0.001). At the 
same time intervals, blood flow increased significantly at 
rim level for group I (+30.03%) (P  0.05) and also when 
all patients were considered (rim +17.99%) (P  0.05). 
Between T1 and T3, there was a significant increase of ODPP 
in group I (+7.24%) (P  0.01) and in group II (+6.08%) 
(P  0.05) and when all patients were considered (+8.43%) 
(P  0.01).36
The improvement in ocular blood flow parameters with 
the fixed combination appears to reflect the activity of the 
dorzolamide 2% component. When included as a comparator, 
timolol 0.5% had no significant effect on ocular blood flow 
markers in these studies.31,37,38 However these improved 
ocular blood flow parameters were not accompanied by any 
enhancement in visual function.35,37
Dosage and administration
Dorzolamide 2%/timolol 0.5% is indicated for the treatment 
of raised IOP in patients with ocular hypertension, open-angle 
glaucoma, pseudoexfoliative glaucoma or other secondary 
open-angle glaucomas when concomitant therapy is 
appropriate. It may be used alongwith prostaglandin analogs 
when IOP control is not possible with a single medication. 
It can also be used when prostaglandin analogs cannot be 
used such as, if patient has a history of herpetic keratitis or 
is concerned about side effects like iris heterochromia and 
periocular pigmentation.
Dorzolamide/timolol should be used with caution in 
those with hepatic insufficiency and is not recommended in 
patients with severe renal impairment (creatinine clearance 
1.8 L/h [30 mL/min]). It is contraindicated in Europe 
in patients with hyperchloremic acidosis. Dorzolamide/
timolol is contraindicated in patients with a history of 
bronchial asthma, severe obstructive pulmonary disease, 
cardiac failure, sinus bradycardia, atrioventricular block or 
cardiogenic shock. Finally, the formulation should not be 
used in patients with known hypersensitivity to either of the 
components (eg, sensitivity to sulfonamides).
Therapeutic efficacy
The fixed combination dorzolamide–timolol has been 
compared with monotherapy dorzolamide 2%,39,40 timolol 
0.5%,39,40 latanoprost 0.005%,41–48 bimatoprost 0.03%,49,50 
travoprost 0.004%,47,48,51 unoprostone 0.15%52 and with 
concomitant therapy with dorzolamide 2% and timolol 
0.5%,53,54 brimonidine 0.2% plus either timolol 0.5%55–58 
or latanoprost 0.005%59 and pilocarpine 2% with timolol 
0.5%.60,61 Recently, it has also been compared with 
fixed combination latanoprost 0.005%/timolol 0.5%,62–64 
brinzolamide 1%/timolol 0.5%65,66 and travoprost 0.004%/
timolol 0.5%67 in randomized clinical trials carried out 
at various centers across the world. Another recent study 
reports the additive effect of dorzolamide 2%/timolol 0.5% 
fixed combination in patients under monotherapy with 
latanoprost.68
Adults with POAG or ocular hypertension who did not 
have any contraindications for the study medications were 
enrolled in these trials. Based on the available demographic 
details, the mean or the median age of trial participants 
ranged from 58.5 to 66.5 years. The subjects were recruited 
if they had a baseline morning trough and/or morning peak 
IOP of  20 mmHg, after completing a 2- to 6-week run in 
period on timolol 0.5% twice daily or a washout period of 
3 to 28 days (depending on drug class).
In most studies the primary efficacy endpoint was the 
mean change in IOP from time-matched baseline values, the 
mean change in diurnal IOP from baseline or the between 
group difference in the mean reduction in daytime diurnal 
IOP from baseline.
Versus concomitant  
or monotherapy
The efficacy of dorzolamide 2%/timolol 0.5% compared with 
mono or concomitant therapy with the same drugs has been 
evaluated in 4 major clinical studies involving a total of 1129 
patients with glaucoma39,40,53,54 (Table 1). All studies were 
multicenter, randomized, parallel and double-blind with active 
controls. Many patients enrolled in these trials were previ-
ously using one or the other antiglaucoma medications.39,40,54 
To establish a comparable baseline, patients underwent 
a 2-53,54 or 3-week40 run-in period on timolol 0.5% twice 
daily, or a washout period of 3 to 21 days depending on the 
medication.39 Where dorzolamide 2%/timolol 0.5% was com-
pared with timolol 0.5% or dorzolamide 2% monotherapy, 
the hypothesis tested was that there was 95% confidence that 
mean IOP in the combined therapy group differed from that 
in the monotherapy groups by 6%40 or 8%.39 Only 1 trial 
reported p values for treatment comparisons.40 The controlled 
study period was 90 days in all trials, with a 9-month 
open-label extension in 1 trial.54 The age at entry was 21 to 
85 years in 3 trials40,53,54 and 21 years in 1 trial.39 The IOP 
at baseline in the worst eye was required to be 22 mmHg 
in 3 of the studies40,53,54 and 24 mmHg in 1 study.39 In all 
studies change in IOP was the primary end-point and was 
measured at trough (0 hours) and peak (2 hours) in relation to 
the morning dose of medication 14, 30, 60 and 90 days after Drug, Healthcare and Patient Safety 2010:2 76
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initiation of therapy. In 1 study, an additional measurement 
was made at 8 hours.53 The concentrations of the individual 
drugs in both the combined and monotherapy formulations 
were dorzolamide 2% and timolol 0.5%. In all studies the 
primary efficacy analyses were based on the last observation 
carried forward approach, although secondary analyses were 
performed using other methods in 3 studies.39,40,53 The studies 
that compared combined and concomitant therapy were 
designed to determine equivalence and this was assessed 
by calculating the 90%54 or 95%53 confidence interval for 
the hypothesis that the mean IOP of each of the 2 treatment 
groups differed by 1.5 mmHg.
Versus prostaglandin analogs
Versus latanoprost 0.005%
Dorzolamide 2%/timolol 0.5% was comparable to latanoprost 
0.005% once daily in two double masked comparisons that 
followed a washout period41 (Table 2). The mean reduction 
of daytime diurnal IOP between the groups from baseline 
at 3 months was within ±1.5 mmHg study 1: -0.04 mmHg 
[95% CI: -0.85, 0.77] in favor of dorzolamide 2%/timolol 
0.5%; study 2: -0.57 mmHg [95% CI: 1.31, 0.16] in favor 
of dorzolamide 2%/timolol 0.5%.
Additional post hoc analyses of pooled data from these 
trials showed dorzolamide 2%/timolol 0.5% and latanoprost 
0.005% were similar with respect to percentages of patients 
achieving target levels of IOP reduction.69
Versus bimatoprost 0.03%
Dorzolamide 2%/timolol 0.5% twice daily lowered IOP less 
consistently than did bimatoprost 0.03% once daily in a double-
masked, parallel-group comparison following a run-in period 
on timolol 0.5% twice daily.49 Mean reductions in IOP from 
baseline at morning trough and peak were greater with bimato-
prost 0.03% at all time points, with the exception of the morning 
peak time point at 3 months.49 Dorzolamide 2%/timolol 0.5% 
Table 1 FCDT vs monotherapy or concomitant therapy with dorzolamide and/or timolol
Authors Time point Treatment N Baseline IOP  
(SD) (mmHg)
Treatment IOP  
(SD) (mmHg)
Change (SD) % change (SD)
Boyle  
et al40
Month 3 trough FCDT 114 27.8 (5.0) 20.1 (4.5) -7.7 (4.2) -27.4 (13.1)
Dorzolamide 109 28.1 (4.7) 23.5 (4.2) -4.6 (4.3) -15.5 (13.5)
Timolol 111 27.9 (4.6) 21.5 (4.0) -6.4 (4.1) -22.2 (12.5)
Month 3 peak FCDT 112 27.1 (4.3) 18.1 (3.8) -9.0 (4.3) -32.7 (12.9)
Dorzolamide 109 27.3 (3.8) 21.8 (4.3) -5.4 (3.6) -19.8 (12.6)
Timolol 110 27.3 (4.4) 21.0 (4.7) -6.3 (4.7) -22.6 (15.6)
Clineschmidt  
et al39
Month 3 trough FCDT 102 25.5 (3.4) 22.7 (3.9) -2.8 (3.4) -10.6 (12.5)
Dorzolamide 51 25.5 (3.8) 24.2 (5.1) -1.4 (4.3) -4.9 (16.7)
Timolol 98 25.2 (3.1) 23.6 (4.3) -1.7 (3.1) -6.7 (11.9)
Month 3 peak FCDT 103 25.0 (3.9) 20.7 (4.5) -4.4 (3.3) -17.3 (12.9)
Dorzolamide 51 24.7 (3.3) 22.7 (3.8) -2.0 (4.1) -7.4 (15.8)
Timolol 95 24.3 (2.6) 22.8 (4.6) -1.6 (3.7) -6.6 (15.3)
Hutzelmann  
et al53
Month 3 FCDT 151 25.6 (3.1) 21.4 (4.1) -4.2 (3.3) -16.3 (12.5)
Trough D + T 148 25.3 (3.2) 21.1 (3.7) -4.2 (3.1) -16.3 (11.5)
FCDT 151 24.7 (3.2) 19.4 (3.7) -5.4 (3.1) -21.6 (12.3)
Month 3 peak D + T 148 24.5 (3.2) 19.1 (3.5) -5.4 (3.3) -21.8 (11.9)
Strohmaier 
et al54
Month 3 FCDT 120 26.1 (3.0) 22.5 (4.1) -3.6 (3.0) -13.8 (11.1)
Trough D + T 121 26.1 (3.8) 22.0 (4.4) -4.1 (3.7) -15.5 (13.8)
FCDT 119 25.1 (3.3) 20.1 (3.8) -5.0 (3.5) -19.7 (12.9)
Month 3 peak D + T 120 25.0 (3.7) 20.2 (4.2) -4.9 (3.8) -19.1 (14.4)
FCDT 116 23.7 (3.9) 20.0 (3.9) -3.7 (3.4) -14.9 (13.2)
Abbreviations: FCDT, fixed combination dorzolamide–timolol; D, dorzolamide; T, timolol.Drug, Healthcare and Patient Safety 2010:2 77
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provided a less stable reduction in IOP over the whole day, as 
evidenced significantly lower mean IOP values in bimatoprost 
0.03% recipients at the 0-, 8- and 12-hour post-dose time points 
at 3 months (P  0.038).49 The percentage of recipients reach-
ing target IOPs of 17 to 20 mmHg was similar between the 
dorzolamide 2%/timolol 0.5% and bimatoprost 0.03% treatment 
groups based on measurements at 0-, 2- and 12-hour post-dose 
time points at 3 months; however, a significantly (P  0.008) 
greater percentage of bimatoprost 0.03% recipients reached the 
lower target pressures 13 mmHg (0% vs 8%), 14 mmHg 
(2% vs 17%), 15 mmHg (9% vs 24%) and 16 mmHg 
(14% vs 31%).49
A relevant concern with this study is whether the selection 
of patients who are inadequately controlled on timolol 
0.5% twice daily provides a valid basis on which to judge 
the relative merits of a timolol-containing therapy versus 
bimatoprost 0.03%.49 Moreover, the study authors did not 
conduct a reverse therapeutic trial and hence did not know 
the number of trial participants who were non-responders 
to timolol.49 Contrasting with the results of this trial, reduc-
tions in day time diurnal IOP (0800–1600 hours) and IOP at 
2 of the 3 measured timepoints (morning peak and 8 hours 
post-dose) were not significantly different with dorzolamide 
2%/timolol 0.5% twice daily vs. bimatoprost 0.03% once 
daily in a small (n = 35), double-masked, cross-over, 3-center, 
8-week study that followed an initial washout period.50
Versus travoprost 0.004%
The IOP-lowering effect of dorzolamide 2%/timolol 0.5% 
twice daily was greater than that of travoprost 0.004% 
once daily in one48 of two small (n = 5045 and 5648), 
single-blind, parallel-group, single-center studies that fol-
lowed a washout period. After 6 months of treatment, the 
reduction in mean diurnal IOP (average of measurements 
made at 0800, 1000 and 1600 hours) from baseline with 
dorzolamide 2%/timolol 0.5% was superior to that with 
travoprost 0.004% (11.5 vs 9.3 mmHg; P  0.05).48 The 
IOP-lowering effect of dorzolamide 2%/timolol 0.5% was 
also greater than that of another comparator, latanoprost 
0.005% once daily (reduction in mean diurnal IOP from 
baseline, 8.2 mmHg; P  0.05 vs dorzolamide/timolol); 
the IOP-lowering effect of the two prostaglandin analogs 
was similar. Of note, this study exclusively enrolled 
patients with pseudoexfoliation glaucoma. Dorzolamide 
2%/timolol 0.5% was, however, less effective than 
travoprost 0.004%47,51 in the other single dose blind, 
  parallel-group, single-center comparison,51 and less effec-
tive than both travoprost 0.004% and latanoprost 0.005% 
Table 2 FCDT vs other prostaglandin analogs
Authors Time point Treatment Mean baseline IOP  
(SD) (mmHg)
Mean treatment IOP  
(SD) (mmHg)
P-value
Orzalesi et al45 Month 1 FCDT 22.6 (2.7) 16.9 (1.4)
Latanoprost 22.6 (2.7) 16.7 (0.6) 0.05
Fechtner et al69 Month 3 (study 1) FCDT 26.1 18.9
Latanoprost 25.6 18.4 0.05
Month 3 (study 2) FCDT 25.3 17.4
Latanoprost 24.7 17.5 0.05
Konstas et al44 Week 6 FCDT 25.8 (1.4) 15.3 (2.0)
Latanoprost 25.8 (1.4) 15.9 (2.3) 0.05
Konstas et al44  
(pseudoexfoliation patients)
Month 2 FCDT 
Latanoprost
31.2 (6.5) 
31.2 (6.5)
18.1 (3.0) 
18.9 (4.1)
 
0.21
Susanna et al42 Month 2 FCDT 23.6 (3.3) 17.2 (3.1)
Latanoprost 23.5 (2.8) 16.6 (3.0) 0.05
Day et al50 Month 2 FCDT 24.8 (2.4) 18.1 (2.8)
Bimatoprost 24.8 (2.4) 17.4 (2.9) 0.35
Ozturk et al46 Month 6 FCDT 24.1 (2.1) 17.6 (2.9)
Bimatoprost 23.7 (2.0) 17.5 (2.3) 0.48
Coleman49 Month 3 (0800 h) FCDT 24.8 (2.5) 19.8
Bimatoprost 25.0 (2.5) 18.2 0.001
Abbreviation: FCDT, fixed combination dorzolamide–timolol.Drug, Healthcare and Patient Safety 2010:2 78
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in a small (n = 38), single-blind, cross-over, single-center 
comparison that followed a run-in period on timolol 0.5% 
twice daily.47 In the parallel-group comparison,51 the reduc-
tions in mean diurnal IOP (average of measurements made 
at 0800, 1200, 1600 and 2000 hours) from baseline were 
significantly less with dorzolamide 2%/timolol 0.5% than 
with travoprost 0.004% after both 3 (23.1% vs 32.7%; 
P  0.01) and 6 (21.7% vs 30.7%; P  0.01) weeks of 
treatment. Similarly, in the cross-over comparison,47 the 
decrease in mean diurnal IOP (average of measurements 
made at 8 am, 10 am and 4 pm) from baseline following 
3 months of treatment with dorzolamide 2%/timolol 0.5% 
(14.3%; P  0.0001 vs baseline) was significantly less than 
that with travoprost 0.004% (18.4%; P  0.0001 vs base-
line and dorzolamide 2%/timolol 0.5%) and latanoprost 
0.005% (22.1%; P  0.0001 vs baseline and dorzolamide 
2%/timolol 0.5%).47 Again, the IOP-lowering effect of the 
two prostaglandin analogs was similar.
Versus unoprostone 0.15% and  
timolol 0.5%
Day et al conducted a prospective multicenter, randomized, 
double-masked, crossover comparison study and found a 
similar efficacy and safety between dorzolamide 2%/timolol 
0.5% and concomitant use of unoprostone 0.15%and timolol 
maleate 0.5% (n = 32).52 After a 4-week run in period on 
timolol 0.5% twice daily, the patients received one treatment 
for 6 weeks and then crossed over to the opposite treatment. 
The authors found comparable IOP reduction for all the time 
points, for the diurnal curve or in the extended reduction from 
baseline52 (Table 3).
Versus latanoprost 0.005%/timolol 0.5%
The reduction in daytime diurnal IOP (0800–1600 hours62 
or 0800–2000 hours63) with dorzolamide 2%/timolol 
0.5% twice daily vs latanoprost 0.005%/timolol 0.5% 
once daily significantly favored the latter in a large 
Table 3 A, B FCDT versus other combination antiglaucoma drugs
A
Authors Time point Treatment Mean baseline IOP  
(SD) (mmHg)
Mean treatment IOP  
(SD) (mmHg)
Treatment difference P-value
Arcieri et al58 Month 1 FCDT 22.9 (1.6) 15.4 (2.1) 0.4 0.43
FCBT 22.9 (1.6) 15.0 (2.1)
Konstas et al63 Month 2 FCDT 20.2 (1.9) 17.0 (2.0) 0.27 0.36
FCLT 20.1 (2.0) 17.3 (2.2)
Shin et al62 Month 3 FCDT 27.5 (3.1) 19.1 (3.3) 0.6 0.005
FCLT 27.9 (3.6) 18.5 (2.9)
Kalzuny et al61 Week 6 trough FCDT 23.4 (2.3) 18.0 (2.2) 0.6 0.22
FCPT 17.4 (2.0)
Diurnal curve FCDT 22.3 (3.7) 18.1 (2.2) 1.4 0.0007
FCPT 16.7 (1.9)
Day et al52 Week 6 trough FCDT 24.3 (3.0) 20.1 (4.5) 0.55
T + U 20.1 (4.5)
Diurnal curve FCDT 23.4 (3.2) 19.8 (4.1) 0.63
T + U 19.8 (4.1)
Teus et al67 Week 6 FCDT 26.1 (0.18) 17.7 (0.25) 0.002
Tr + T 26 (0.18) 16.6 (0.26) 1.1
B
Zabriskie and  
Netland59
Month 3 (study 1) FCDT 6.5 25.3
B + L 9.0 33.9 0.044
Month 3 (study 2) FCDT 6.6 26.3
B + L 9.1 33.4 0.047
Abbreviations: FCDT, fixed combination dorzolamide–timolol; FCBT, fixed combination brimonidine–timolol; FCPT, fixed combination pilocarpine; timolol; FCLT, fixed 
combination latanoprost–timolol; T + U, timolol + unoprostone; Tr + T, travoprost + timolol; B + L, brimonidine + latanoprost.Drug, Healthcare and Patient Safety 2010:2 79
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(n = 253), single-blind, parallel-group trial preceded by a 
washout period.62 However, the between-group difference 
after 3 months’ treatment (primary endpoint) was only 
1.0 mmHg (95% CI 0.4, 1.69; P = 0.005) and the clini-
cal relevance of this small difference is questionable.62 
Daytime diurnal IOP was not significantly different fol-
lowing treatment with these two fixed combinations in a 
small (n = 33) double-masked, cross-over comparison that 
followed a run-in period on timolol 0.5% twice daily.63 
For other endpoints in these studies, mean reductions in 
IOP were significantly less with dorzolamide 2%/timolol 
0.5% than with latanoprost 0.005%/timolol 0.5% at morn-
ing trough (8.1 vs 9.6 mmHg; P = 0.007) and the 8-hour 
post-dose timepoint (8.3 vs 9.5 mmHg; P = 0.014) after 
3 months’ treatment in the larger trial,62 but not at the 
corresponding timepoints after 2 months’ treatment in 
the smaller trial.63 Conversely, mean IOP values favored 
dorzolamide 2%/timolol 0.5% over latanoprost 0.005%/
timolol 0.5% at morning peak (17.3 vs 17.8 mmHg; 
P = 0.04) and the 4-hour post dose timepoint (16.7 vs 
17.5 mmHg; P = 0.03) after 2 months’ treatment in the 
smaller comparison,63 but not at the 4-hour post-dose time-
point after 3 months’ treatment in the larger comparison 
(18.6 vs. 18.5 mmHg).62 In the larger trial,62 consistently 
fewer dorzolamide 2%/timolol 0.5% than latanoprost 
0.005%/timolol 0.5% recipients achieved specific reduc-
tions (range 5% to 40%) in daytime diurnal IOP at 
3 months; these between group differences were statisti-
cally significant for the 15% (92% vs 99%; P  0.05), 
20% (80% vs 92%; P  0.01), 25% (66% vs 81%; 
P  0.01) and 30% (50% vs 67%; P  0.01) reduction 
levels (values estimated from a graph) (Table 3).
Versus brimonidine 0.2%/timolol 0.5%
Nixon et al presented a pooled data analysis of 2 random-
ized, investigator-masked, 3-month, parallel-group stud-
ies with identical protocols (10 sites) (n = 180). Patients 
received topical brimonidine 0.2%/timolol 0.5% twice 
daily or dorzolamide 2%/timolol 0.5% twice daily as mono-
therapy (n = 101) or as adjunctive therapy to a prostaglandin 
analog (latanoprost, bimatoprost, or travoprost) (n = 79). 
At month 3, the mean (SD) reduction from baseline IOP 
for patients on fixed-combination monotherapy was 7.7 
(4.2) mmHg (32.3%) with brimonidine 0.2%/timolol 0.5% 
vs 6.7 (5.0) mmHg (26.1%) with dorzolamide 2%/timolol 
0.5% (P  0.040).The mean reduction from prostaglandin 
analog-treated baseline IOP for patients on fixed-combination 
adjunctive therapy was 6.9 (4.8) mmHg (29.3%) with brimo-
nidine 0.2%/timolol 0.5% vs 5.2 (3.7) mmHg (23.5%) with 
dorzolamide 2%/timolol 0.5% (P = 0.213).57
According to preliminary results from a small (n = 30), 
single-blind trial of cross-over, multicenter design and 
3 month duration, the mean reduction in morning peak IOP 
from baseline at 3 months was 3.0 mmHg in the dorzolamide 
2%/timolol 0.5% group versus 6.8 mmHg in the brimonidine 
0.2%/timolol 0.5% group (P = 0.02).58
Versus brinzolamide1%/timolol 0.5%
In a 1-year, multicenter, randomized, double masked, 
active-controlled, parallel-group trial of brinzolamide 
0.1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% with 
437 patients, 220 were dosed brinzolamide 0.1%/timolol 
0.5% and 217 received dorzolamide 2%/timolol 0.5%. IOP 
assessments were taken at 0800 and 1000 hours at week 2 
and months 3 and 9, and at 0800, 1000, and 1600 hours at 
months 6 and 12.65 Brinzolamide 0.1%/timolol 0.5% produced 
IOP-lowering efficacy comparable to dorzolamide 2%/timolol 
0.5%, with the upper 95% confidence limits for the differences 
between groups within +1.5 mmHg at all assessment times, 
including the month 6 primary efficacy time points, estab-
lishing noninferiority. The IOP reductions ranged from 7.2 
to 9.2 mmHg for brinzolamide 0.1%/timolol 0.5% and from 
7.4 to 8.9 mmHg for dorzolamide 2%/timolol 0.5%.
Versus travoprost 0.004%/timolol 0.5%
In a multicenter, double-masked, randomized clinical trial, 
319 patients received either travoprost 0.004%/timolol 
0.5% once daily in the morning (n = 157) or dorzolamide 
2%/timolol 0.5% twice daily (n = 162).67 IOP was assessed 
morning and evening at 2 and 6 weeks. Mean pooled diurnal 
IOP was significantly lower in the travoprost 0.004%/timolol 
0.5% group (16.5 mmHg ± 0.23) than in the dorzolamide 
2%/timolol 0.5% group (17.3 mmHg ± 0.23; P = 0.011). 
Moreover, travoprost 0.004%/timolol 0.5% combination 
produced superior mean IOP reductions from baseline of 
35.3% to 38.5%, while the dorzolamide 2%/timolol 0.5% 
combination produced mean IOP reductions from baseline 
of 32.5% to 34.5%.
Versus timolol 0.5% and pilocarpine 2%
Dorzolamide 2%/timolol 0.5% was as effective as timolol 
0.5% plus pilocarpine 2% in patients with glaucoma or 
ocular hypertension and was the preferred formulation. The 
dorzolamide/timolol has been compared with concomitant 
pilocarpine and timolol therapy in 2 trials (published as a 
single report).60 Two randomized trials with identical drug Drug, Healthcare and Patient Safety 2010:2 80
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administration and assessment protocols were performed; 
1 in the US and 1 internationally (5 countries). Patients 
18 years with baseline IOP of  22 mmHg after a 
3-week run-in with timolol 0.5% twice daily were assigned 
to receive dorzolamide 2%/timolol 0.5% twice daily or 
timolol (0.5%) twice daily plus pilocarpine (2.0%) 4 times 
daily for 14 days. After a 7-day wash-out period, patients 
crossed over to receive the alternative therapy for a further 
14 days. There were 97 patients in the US study and 93 in 
the international trial. The primary endpoints were patient 
preference and impact on daily life, and were assessed by 
a questionnaire administered by study physicians. IOP was 
also measured at baseline and on days 15, 22 and 36 at 2 and 
4 hours after drug administration; only the IOP values from 
day 36 were published. After the 36-day study period there 
were no significant differences in IOP between the 2 treat-
ment groups in either study.50 In the US study, the peak (2-
hour) IOP in the dorzolamide/timolol group dropped from 
23.7 mmHg at baseline to 19.8 mmHg at 36 days, and the 
corresponding values for the timolol plus pilocarpine con-
comitant therapy group were 23.5 mmHg at baseline and 
20.1 mmHg at 36 days. In the international study, baseline 
peak IOP in the dorzolamide 2%/timolol 0.5% group was 
24.4 mmHg dropping to 19.1 mmHg after 36 days, while 
peak IOP in the concomitant therapy group was 24.4 mmHg 
at baseline and 18.7 mmHg at the end of the trial. In both 
studies, patients preferred dorzolamide/timolol combina-
tion to concomitant therapy with timolol and pilocarpine 
by a ratio of approximately 4:1. The primary reason for 
this preference was the reduced frequency and severity 
of adverse effects although patients also reported that the 
combination therapy interfered less with daily life. Com-
pliance was also improved and patients reported missing 
fewer doses with the twice daily combined therapy.
Kalzuny et al conducted a 6 week trial to compare the 
efficacy and safety of dorzolamide 2%/timolol 0.5% with 
fixed combination pilocarpine timolol, each given twice daily, 
in patients with POAG or ocular hypertensive patients. They 
found that both combinations were equally efficacious in IOP 
reduction61 (Table 3).
Safety and tolerability
Tolerability of a drug has been identified as a barrier to compli-
ance.70 The adverse event profile of dorzolamide 2%/timolol 
0.5% mirrors that of the individual components and consists 
primarily of ocular and local adverse events. The most com-
mon adverse events associated with dorzolamide (Trusopt®; 
Merck & Co., Inc., Whitehouse Station, NJ, USA) are ++ burn-
ing, stinging, and discomfort, and taste perversion (Trusopt® 
prescribing information, Merck & Co., Inc., 2005; http://www.
merck.com/product/usa/pi_circulars/t/trusopt/trusopt_pi.pdf); 
a similar safety profile is observed with the dorzolamide 2%/
timolol 0.5% fixed combination (Cosopt®) (Cosopt® prescrib-
ing information, Merck & Co., Inc., 2006; http://www.merck.
com/product/usa/pi_circulars/c/cosopt.html).
Dorzolamide 2%/timolol 0.5% twice daily was 
generally well tolerated in large (n = 177–492) trials of 3 to 
6 months duration which evaluated this fixed combination 
in relation to the individual components, given either as 
monotherapy or concomitantly, or against other ocular 
hypotensive agents.39–43,49,53–56,62 Between 33% and 77% 
of patients receiving dorzolamide 2%/timolol 0.5% 
in these studies reported adverse events (regardless of 
cause);39–45,53,54,65 10% to 68% reported drug-related adverse 
events.42,43,53–56,67 Transient and mild to moderate burning 
and/or stinging39–41,45,49,53–56 of the eye (5%–41%) was the 
most commonly reported ocular adverse event in majority 
of the trials. Dysgeusia39–41,49,53–56 (2%–38%) was the most 
common local adverse effect.
Recently, timolol 0.5% and brinzolamide 1% (Azopt®; 
Alcon Laboratories, Inc., Ft. Worth, TX, USA) have 
been formulated in a fixed combination (Azarga™; Alcon 
Laboratories, Inc., Ft. Worth, TX, USA). The most common 
side effects with brinzolamide 1% are blurred vision and 
taste perversion; fewer than 5% of patients report ocular 
discomfort associated with brinzolamide use in clinical trials 
(Azopt® prescribing in formation, Alcon Laboratories, Inc. 
2003; http://ecatalog.alcon.com/pi/Azopt_us_en.pdf). In a 
prospective, double-masked, randomized, active-controlled, 
crossover, multicenter study, 127 patients received 1 drop of 
brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 
0.5% in both eyes on consecutive days in random order. 
Ocular discomfort was rated 1 minute after instillation of 
each medication, and preference was noted on Day 2. Of 
the 106 subjects who expressed a drug preference, 79.2% 
preferred brinzolamide 1%/timolol 0.5% (P  0.0001). 
Ocular discomfort scores were significantly higher with 
dorzolamide 2%/timolol 0.5% than brinzolamide 1%/timolol 
0.5% (2.9 vs 1.4, respectively; P  0.0001). Significantly 
more patients reported ocular pain and discomfort after 
dorzolamide 2%/timolol 0.5% instillation and transient 
blurred vision after brinzolamide 1%/timolol 0.5% 
instillation.66 Manni et al observed a similar overall safety 
profile between the two groups, but brinzolamide 1%/timolol 
0.5% showed significantly less ocular irritation (2.7% vs 
10.6%; P = 0.0009) than dorzolamide 2%/timolol 0.5%.65Drug, Healthcare and Patient Safety 2010:2 81
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Teus et al have shown statistically significant difference 
in the amount of conjunctival hyperemia in travoprost 
0.004%/timolol 0.5% group compared to dorzolamide 2%/
timolol 0.5%, but it does not present any untoward safety 
issues.67
Long-term tolerability data are limited, although fixed 
combination was generally well tolerated for up to 1 year in 
a non-blind extension of one study.54
Conclusions
Efficacy and safety studies published till date show 
that dorzolamide with timolol is more efficacious 
than the individual components, and as effective as 
the  components  used  concomitantly  in  controlled 
settings. Dorzolamide–timolol also has efficacy com-
parable to latanoprost 0.004%, pilocarpine 2%/timolol 
0.5%, brinzolamide 0.1%/timolol 0.5% and unoprostone 
0.15%/timolol 0.5% KLC. Dorzolamide-timolol is slightly 
more efficacious than latanoprost 0.005%/timolol 0.05% 
and brimonidine 0.2%/timolol 0.5%. In conclusion, 
dorzolamide–timolol combination has a good efficacy, 
safety and tolerability profile and hence an increased patient 
compliance.
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